

SUNDAY, SEPTEMBER 25, 2022 | 12:30 - 1:30 PM CT

Please join us for a discussion on a treatment option in the *EGFR* exon 20 insertion NSCLC space including disease state, mechanism of action, clinical trial data, and management of adverse reactions including infusion-related reactions.

## **AGENDA**

- Welcome and introductions
- Testing and EGFR exon 20 insertions
- A treatment option in EGFR exon 20 insertion NSCLC
  - Introduction
  - Efficacy and safety

- Infusion-related reactions (IRR)
  - Recommendations for managing IRR
- Important Safety Information
- Summary
- Q&A session



## **SPEAKER**

David M. Waterhouse, MD, MPH

Senior Network Physician

Associate Medical Director, DFCI Network Host Hospital/System Relations
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center

**DISCLAIMER:** This educational event is sponsored by Janssen Biotech, Inc., and is not certified for continuing medical education. The speaker is a paid consultant of Janssen Biotech, Inc., and must present information in compliance with FDA requirements applicable to Janssen Biotech, Inc.

This presentation was approved by the IASLC as an independent activity held in conjunction with the 2022 North America Conference on Lung Cancer. This presentation is not sponsored or endorsed by NACLC and is not part of the official IASLC accredited program.

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs. For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements. Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials.

